Molecure gets IDMC nod to continue Phase II KITE trial of OATD-01 in pulmonary sarcoidosis without protocol changes

• Molecure received an Independent Data Monitoring Committee recommendation to continue its Phase II KITE trial of OATD-01 without protocol changes.
• Interim results were reviewed from the first 30 patients; unblinded futility analysis supported a viable path to the primary endpoint.
• Blinded biomarker readouts showed trends consistent with the drug’s expected anti-inflammatory effect, without drawing final efficacy conclusions.
• The study is still enrolling for a second and final interim analysis, which will reassess the required sample size.
• Unblinded trial results will be presented in the future once the study is completed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Molecure SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608031201OMX_____CNEWS_EN_GNW1001255861_en) on August 03, 2026, and is solely responsible for the information contained therein.